title: QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin.
abstract: Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transforming growth factor-β1 (TGF-β1)-responsive α-smooth muscle actin (α-SMA), collagen I, and fibronectin up-regulation in obstructive nephropathy and cultured cells. Administration of QSYQ also inhibited the established renal interstitial fibrosis in obstructive nephropathy. Interestingly, QSYQ selectively inhibited TGF-β1-induced β-catenin up-regulation and downstream gene transcription. Taken together, our study suggests that QSYQ selectively inhibits TGF-β1-induced β-catenin up-regulation and might have significant therapeutic potential for the treatment of renal fibrosis.
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Zhanmei
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Hu
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Fengxin
authors.initials: F
authors.lastname: Zhu
authors.affiliation: Tasly R&D Institute, Tianjin, P.R. China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Nie
authors.affiliation: State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Jun
authors.identifier: http://orcid.org/0000-0001-6650-3944
authors.initials: J
authors.lastname: Ai
mesh_terms: D000199:Actins / Q000037:antagonists & inhibitors; D000818:Animals; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005355:Fibrosis / Q000188:drug therapy; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*; D014158:Transcription, Genetic; D053773:Transforming Growth Factor beta1 / Q000502:physiology; D051176:beta Catenin / Q000378:metabolism*
chemical_list: D000199:Actins; D004365:Drugs, Chinese Herbal; D053773:Transforming Growth Factor beta1; D051176:beta Catenin; C528580:qishen yiqi; C498862:Acta2 protein, rat